

## PROXY/POSTAL VOTE FORM

The annual general meeting of Scandion Oncology A/S ("Scandion Oncology" or the "Company") on 27 March 2025, at 14.00 (CET) at the Company's address Fruebjergvej 3, DK-2100 Copenhagen Ø, Denmark

| A    | Name of shareholder:  Address:  Zip code and city:   |          |
|------|--|----------|
|      | indersigned, hereby grant authority by proxy or vote by post at the annual general meeting of Scandion eld on <b>27 March 2025</b> as set out below:   | Oncology |
|      | mark the appropriate box A), B), C), or D). Please note that it is only possible either to grant ity by proxy or to vote by post.  |          |
| A) 🗆 | Proxy is given to an identified third person:  |          |
|      | Name and address of the proxy holder (CAPITAL LETTERS)   |          |
| B) 🗆 | Proxy is given to the board of directors (with a right of substitution) to vote in accordance with the recommendations of the board of directors as stated in the table below.                                 |          |
| C) 🗆 | Proxy is given to the board of directors (with a right of substitution) to vote in accordance with the vo directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your direction | _        |
| D) 🗆 | The postal vote is given in accordance with the voting directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your directions. The postal vote is irrevocable.                  |          |
|      |  |          |

| Ite<br>(the | ems on the agenda<br>e full agenda is included in the notice of the meeting)          | FOR | AGAINST | ABSTAIN | The board's recommendation |
|-------------|---|-----|---------|---------|----------------------------|
| 1.          | Election of chairman of the meeting (Ms. Hjerrild)                                    |     | *       |         | FOR                        |
| 2.          | Report from the board of directors on the Company's activities in the past year       |     |         |         | FOR                        |
| 3.          | Presentation of the audited annual report for approval                                |     |         |         | FOR                        |
| 4.          | Proposal of notice of discharge for the board of directors and the executive board    |     |         |         | FOR                        |
| 5.          | Decision on appropriation of profit or loss as recorded in the approved annual report |     |         |         | FOR                        |
| 6.          | Proposal to enter into voluntary solvent liquidation                                  |     |         |         | FOR                        |
| 7.          | Proposal to elect a liquidator (Johnny Stilou)  |     | *       |         | FOR                        |
| 8.          | Proposal of approval of the board of directors' fee for Q1 2025                       |     |         |         | FOR                        |



| 9. Election of members to the board of directors**   | * |      | ABSTAIN |
|--|---|------|---------|
| 9. Election of members to the board of directors**  A) Election of  B) Election of  C) Election of  D) Election of  E) Election of | * | 0000 | ABSTAIN |
| 10. Election of auditor (Deloitte)   | * |      | FOR     |

A form that has only been dated and signed shall be considered as a proxy given to the board of directors to vote in accordance with the recommendations of the board of directors as they appear in the table above.

The proxy shall apply to all subjects discussed at the annual general meeting. If new proposals are presented and put to the vote, including proposals for amendments, the proxy holder shall be entitled to vote on your behalf in accordance with his or her own convictions.

The proxy/vote by correspondence applies to the number of shares in the possession of the undersigned on the date of registration, 20 March 2025. The shareholding is calculated on the basis of the entry in the Company's register of shareholders and notifications on ownership that the Company has received, but not yet entered in the register of shareholders.

The Company requests that the completed and signed form is received by the Company at the address Fruebjergvej 3, DK-2100 Copenhagen  $\emptyset$ , or by e-mail to: gm@scandiononcology.com no later than 24 March 2025 at 11.59 p.m. (CET).

|  | 1 1 2 | 2 | 0 | 2 | 5 |           |
|--|-------|---|---|---|---|-----------|
|  |       |   |   |   |   | Signature |

<sup>\*</sup>In connection with the election of persons (election of chairman of the meeting (item 1), election of liquidator (item 7), members of the board of directors (item 9) and auditor (item 10)), it is legally speaking only possible to vote in <u>favour</u> of the proposed candidates or in <u>favour</u> of alternative candidates proposed for the positions in question. Consequently, the proxy/postal vote form cannot be used to vote <u>against</u> the proposed candidates.

<sup>\*\*</sup>Item 9 will automatically be removed from the agenda if the board of directors' proposal for the Company to enter into voluntary solvent liquidation (item 6) is adopted. As no candidates have been proposed, it is only possible to vote in favor of a candidate that you propose by adding their name to the form. It is only allowed to propose a candidate who have agreed to be up for election.